164 related articles for article (PubMed ID: 37345085)
1. Androgen Receptor Is Expressed in the Majority of Breast Cancer Brain Metastases and Is Subtype-Dependent.
Fan KY; Chehade R; Qazi M; Moravan V; Nofech-Mozes S; Jerzak KJ
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345085
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression in breast cancer brain metastases.
Chehade R; Qazi MA; Ennis M; Sahgal A; Das S; Nofech-Mozes S; Jerzak KJ
Neurooncol Adv; 2022; 4(1):vdac154. PubMed ID: 36299795
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study.
Gao YK; Kuksis M; Id Said B; Chehade R; Kiss A; Tran W; Sickandar F; Sahgal A; Warner E; Soliman H; Jerzak KJ
Oncologist; 2021 Nov; 26(11):e1951-e1961. PubMed ID: 34506676
[TBL] [Abstract][Full Text] [Related]
4. Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada.
Wang XY; Rosen MN; Chehade R; Sahgal A; Das S; Warner E; Saskin R; Zhang B; Soliman H; Chan KKW; Jerzak KJ
JAMA Netw Open; 2022 Aug; 5(8):e2225424. PubMed ID: 35960523
[TBL] [Abstract][Full Text] [Related]
7. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor is Expressed in Breast Cancer Brain Metastases.
Bergen ES; Berghoff AS; Steindl A; Rajky O; Mercea PA; Kiesel B; Tendl-Schulz K; Bago-Horvath Z; Exner R; Fitzal F; Dieckmann K; Widhalm G; Steger GG; Preusser M; Bartsch R
Appl Immunohistochem Mol Morphol; 2021 Nov-Dec 01; 29(10):728-733. PubMed ID: 34121071
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
11. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer.
Prabhu JS; Korlimarla A; Rajarajan S; Alexander A; Anupama C; Ramesh R; Srinath B; Sridhar TS
Cancer Res; 2021 Feb; 81(4 Suppl):. PubMed ID: 34421401
[TBL] [Abstract][Full Text] [Related]
12. The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis.
Poletes C; Amanirad B; Santiago AT; Yan M; Conrad T; Jerzak KJ; Shultz DB
J Neurooncol; 2024 May; ():. PubMed ID: 38740672
[TBL] [Abstract][Full Text] [Related]
13. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
14. Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer.
Angajala A; Mothershed E; Davis MB; Tripathi S; He Q; Bedi D; Dean-Colomb W; Yates C
Transl Oncol; 2019 Mar; 12(3):493-501. PubMed ID: 30594038
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
[TBL] [Abstract][Full Text] [Related]
16. The expression of androgen receptor in triple-negative breast cancer and the effect of a traditional Chinese medicine formula on disease-free survival.
Yu L; Yu Q; Xu C; Wang M; Song J; Gao X
Gland Surg; 2022 Nov; 11(11):1772-1783. PubMed ID: 36518802
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy.
Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY
Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.
Routh ED; Van Swearingen AED; Sambade MJ; Vensko S; McClure MB; Woodcock MG; Chai S; Cuaboy LA; Wheless A; Garrett A; Carey LA; Hoyle AP; Parker JS; Vincent BG; Anders CK
Front Oncol; 2022; 12():818693. PubMed ID: 35992833
[TBL] [Abstract][Full Text] [Related]
19. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
20. Brain Metastases in the Setting of Stable Versus Progressing Extracranial Disease Among Patients With Metastatic Breast Cancer.
Kojundzic I; Chehade R; Gonzalez CAC; Fritz J; Moravan V; Sahgal A; Warner E; Das S; Jerzak KJ
Clin Breast Cancer; 2024 Feb; 24(2):156-161. PubMed ID: 38135543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
